Corpus
PascalFrancis
Racine
Corpus
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of De Novo infection by HIV

Identifieur interne : 000118 ( PascalFrancis/Corpus ); précédent : 000117

Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of De Novo infection by HIV

Auteurs : C. A. Stein ; M. Matsukura ; C. Subasinghe ; S. Broder ; J. S. Cohen

Source :

RBID : Pascal:90-0168889

Descripteurs français

English descriptors

Abstract

We have now synthesized a series of phosphorothioate oligomers with mixed-based sequences and found that all of them have a dose-dependent cytoprotective effect that is maximal at an oligomer concentration of about 1-2 μM. The least effective sequences contain only A or T, and the most effective sequences have 40% GC content or greater. The results also confirm the length effect, namely that 21-mers are more cytoprotective than 14-mers

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  2    @0 53157X
A02 01      @0 ARHRE7
A03   1    @0 AIDS res. hum. retroviruses
A05       @2 5
A06       @2 6
A08 01  1  ENG  @1 Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of De Novo infection by HIV
A11 01  1    @1 STEIN (C. A.)
A11 02  1    @1 MATSUKURA (M.)
A11 03  1    @1 SUBASINGHE (C.)
A11 04  1    @1 BRODER (S.)
A11 05  1    @1 COHEN (J. S.)
A14 01      @1 National cancer inst. @2 Bethesda MD 20892 @3 USA @Z A11011000
A20       @1 639-646
A21       @1 1989
A23 01      @0 ENG
A43 01      @1 CNRS @2 20934
A44       @0 0000
A45       @0 19 ref.
A47 01  1    @0 90-0168889
A60       @1 P
A61       @0 A
A64   1    @0 AIDS research and human retroviruses
A66 01      @0 USA
C01 01    ENG  @0 We have now synthesized a series of phosphorothioate oligomers with mixed-based sequences and found that all of them have a dose-dependent cytoprotective effect that is maximal at an oligomer concentration of about 1-2 μM. The least effective sequences contain only A or T, and the most effective sequences have 40% GC content or greater. The results also confirm the length effect, namely that 21-mers are more cytoprotective than 14-mers
C02 01  X    @0 002A05C08
C03 03  X  FRE  @0 Analogue
C03 04  X  FRE  @0 Oligonucléotide
C03 05  X  FRE  @0 Synthèse chimique
C03 06  X  FRE  @0 Produit synthétique
C03 08  X  FRE  @0 Protection
C03 09  X  FRE  @0 Cytopathologie
C03 10  X  FRE  @0 Virose
C03 11  X  FRE  @0 Relation dose réponse
C03 13  X  FRE  @0 Culture cellulaire
C03 14  X  FRE  @0 Cellule infectée
C03 16  X  FRE  @0 Oligodésoxyribonucléotide
C03 18  X  FRE  @0 Inhibition
C03 19  X  FRE  @0 Antiviral
C03 21  X  FRE  @0 Virus immunodéficience humaine
C03 22  X  FRE  @0 Phosphorothioate @4 INC
C03 03  X  ENG  @0 Analog
C03 04  X  ENG  @0 Oligonucleotide
C03 05  X  ENG  @0 Chemical synthesis
C03 06  X  ENG  @0 Synthetic product
C03 08  X  ENG  @0 Protection
C03 09  X  ENG  @0 Cytopathology
C03 10  X  ENG  @0 Viral disease
C03 11  X  ENG  @0 Dose activity relation
C03 13  X  ENG  @0 Cell culture
C03 14  X  ENG  @0 Infected cell
C03 16  X  ENG  @0 Oligodeoxyribonucleotide
C03 18  X  ENG  @0 Inhibition
C03 19  X  ENG  @0 Antiviral
C03 21  X  ENG  @0 Human immunodeficiency virus
C03 03  X  SPA  @0 Análogo
C03 04  X  SPA  @0 Oligonucleótido
C03 05  X  SPA  @0 Síntesis química
C03 06  X  SPA  @0 Producto sintético
C03 08  X  SPA  @0 Protección
C03 09  X  SPA  @0 Citopatología
C03 10  X  SPA  @0 Virosis
C03 11  X  SPA  @0 Relación dosis respuesta
C03 13  X  SPA  @0 Cultivo celular
C03 14  X  SPA  @0 Célula infectada
C03 16  X  SPA  @0 Oligodesoxirribonucleótido
C03 18  X  SPA  @0 Inhibición
C03 19  X  SPA  @0 Antiviral
C03 21  X  SPA  @0 Human immunodeficiency virus
C04 01  X    @0 PS21!04,26,19
C07 01  X  FRE  @0 Infection
C07 02  X  FRE  @0 Retroviridae
C07 03  X  FRE  @0 Virus
C07 04  X  ENG  @0 Infection
C07 05  X  ENG  @0 Retroviridae
C07 06  X  ENG  @0 Virus
C07 07  X  SPA  @0 Infección
C07 08  X  SPA  @0 Retroviridae
C07 09  X  SPA  @0 Virus
N21       @1 005

Format Inist (serveur)

NO : PASCAL 90-0168889 INIST
ET : Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of De Novo infection by HIV
AU : STEIN (C. A.); MATSUKURA (M.); SUBASINGHE (C.); BRODER (S.); COHEN (J. S.)
AF : National cancer inst./Bethesda MD 20892/Etats-Unis (A11011000)
DT : Publication en série; Niveau analytique
SO : AIDS research and human retroviruses; ISSN 53157X; Coden ARHRE7; Etats-Unis; Da. 1989; Vol. 5; No. 6; Pp. 639-646; Bibl. 19 ref.
LA : Anglais
EA : We have now synthesized a series of phosphorothioate oligomers with mixed-based sequences and found that all of them have a dose-dependent cytoprotective effect that is maximal at an oligomer concentration of about 1-2 μM. The least effective sequences contain only A or T, and the most effective sequences have 40% GC content or greater. The results also confirm the length effect, namely that 21-mers are more cytoprotective than 14-mers
CC : 002A05C08
FD : Analogue; Oligonucléotide; Synthèse chimique; Produit synthétique; Protection; Cytopathologie; Virose; Relation dose réponse; Culture cellulaire; Cellule infectée; Oligodésoxyribonucléotide; Inhibition; Antiviral; Virus immunodéficience humaine; Phosphorothioate
FG : Infection; Retroviridae; Virus
ED : Analog; Oligonucleotide; Chemical synthesis; Synthetic product; Protection; Cytopathology; Viral disease; Dose activity relation; Cell culture; Infected cell; Oligodeoxyribonucleotide; Inhibition; Antiviral; Human immunodeficiency virus
EG : Infection; Retroviridae; Virus
SD : Análogo; Oligonucleótido; Síntesis química; Producto sintético; Protección; Citopatología; Virosis; Relación dosis respuesta; Cultivo celular; Célula infectada; Oligodesoxirribonucleótido; Inhibición; Antiviral; Human immunodeficiency virus
LO : CNRS-20934
ID : 90-0168889

Links to Exploration step

Pascal:90-0168889

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of De Novo infection by HIV</title>
<author>
<name sortKey="Stein, C A" sort="Stein, C A" uniqKey="Stein C" first="C. A." last="Stein">C. A. Stein</name>
</author>
<author>
<name sortKey="Matsukura, M" sort="Matsukura, M" uniqKey="Matsukura M" first="M." last="Matsukura">M. Matsukura</name>
</author>
<author>
<name sortKey="Subasinghe, C" sort="Subasinghe, C" uniqKey="Subasinghe C" first="C." last="Subasinghe">C. Subasinghe</name>
</author>
<author>
<name sortKey="Broder, S" sort="Broder, S" uniqKey="Broder S" first="S." last="Broder">S. Broder</name>
</author>
<author>
<name sortKey="Cohen, J S" sort="Cohen, J S" uniqKey="Cohen J" first="J. S." last="Cohen">J. S. Cohen</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">90-0168889</idno>
<date when="1989">1989</date>
<idno type="stanalyst">PASCAL 90-0168889 INIST</idno>
<idno type="RBID">Pascal:90-0168889</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000118</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of De Novo infection by HIV</title>
<author>
<name sortKey="Stein, C A" sort="Stein, C A" uniqKey="Stein C" first="C. A." last="Stein">C. A. Stein</name>
</author>
<author>
<name sortKey="Matsukura, M" sort="Matsukura, M" uniqKey="Matsukura M" first="M." last="Matsukura">M. Matsukura</name>
</author>
<author>
<name sortKey="Subasinghe, C" sort="Subasinghe, C" uniqKey="Subasinghe C" first="C." last="Subasinghe">C. Subasinghe</name>
</author>
<author>
<name sortKey="Broder, S" sort="Broder, S" uniqKey="Broder S" first="S." last="Broder">S. Broder</name>
</author>
<author>
<name sortKey="Cohen, J S" sort="Cohen, J S" uniqKey="Cohen J" first="J. S." last="Cohen">J. S. Cohen</name>
</author>
</analytic>
<series>
<title level="j" type="main">AIDS research and human retroviruses</title>
<title level="j" type="abbreviated">AIDS res. hum. retroviruses</title>
<idno type="ISSN">53157X</idno>
<imprint>
<date when="1989">1989</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">AIDS research and human retroviruses</title>
<title level="j" type="abbreviated">AIDS res. hum. retroviruses</title>
<idno type="ISSN">53157X</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Analog</term>
<term>Antiviral</term>
<term>Cell culture</term>
<term>Chemical synthesis</term>
<term>Cytopathology</term>
<term>Dose activity relation</term>
<term>Human immunodeficiency virus</term>
<term>Infected cell</term>
<term>Inhibition</term>
<term>Oligodeoxyribonucleotide</term>
<term>Oligonucleotide</term>
<term>Protection</term>
<term>Synthetic product</term>
<term>Viral disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Analogue</term>
<term>Oligonucléotide</term>
<term>Synthèse chimique</term>
<term>Produit synthétique</term>
<term>Protection</term>
<term>Cytopathologie</term>
<term>Virose</term>
<term>Relation dose réponse</term>
<term>Culture cellulaire</term>
<term>Cellule infectée</term>
<term>Oligodésoxyribonucléotide</term>
<term>Inhibition</term>
<term>Antiviral</term>
<term>Virus immunodéficience humaine</term>
<term>Phosphorothioate</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">We have now synthesized a series of phosphorothioate oligomers with mixed-based sequences and found that all of them have a dose-dependent cytoprotective effect that is maximal at an oligomer concentration of about 1-2 μM. The least effective sequences contain only A or T, and the most effective sequences have 40% GC content or greater. The results also confirm the length effect, namely that 21-mers are more cytoprotective than 14-mers</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="2">
<s0>53157X</s0>
</fA01>
<fA02 i1="01">
<s0>ARHRE7</s0>
</fA02>
<fA03 i2="1">
<s0>AIDS res. hum. retroviruses</s0>
</fA03>
<fA05>
<s2>5</s2>
</fA05>
<fA06>
<s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of De Novo infection by HIV</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>STEIN (C. A.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>MATSUKURA (M.)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>SUBASINGHE (C.)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>BRODER (S.)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>COHEN (J. S.)</s1>
</fA11>
<fA14 i1="01">
<s1>National cancer inst.</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>A11011000</sZ>
</fA14>
<fA20>
<s1>639-646</s1>
</fA20>
<fA21>
<s1>1989</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>CNRS</s1>
<s2>20934</s2>
</fA43>
<fA44>
<s0>0000</s0>
</fA44>
<fA45>
<s0>19 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>90-0168889</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i2="1">
<s0>AIDS research and human retroviruses</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>We have now synthesized a series of phosphorothioate oligomers with mixed-based sequences and found that all of them have a dose-dependent cytoprotective effect that is maximal at an oligomer concentration of about 1-2 μM. The least effective sequences contain only A or T, and the most effective sequences have 40% GC content or greater. The results also confirm the length effect, namely that 21-mers are more cytoprotective than 14-mers</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002A05C08</s0>
</fC02>
<fC03 i1="03" i2="X" l="FRE">
<s0>Analogue</s0>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Oligonucléotide</s0>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Synthèse chimique</s0>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Produit synthétique</s0>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Protection</s0>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Cytopathologie</s0>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Virose</s0>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Relation dose réponse</s0>
</fC03>
<fC03 i1="13" i2="X" l="FRE">
<s0>Culture cellulaire</s0>
</fC03>
<fC03 i1="14" i2="X" l="FRE">
<s0>Cellule infectée</s0>
</fC03>
<fC03 i1="16" i2="X" l="FRE">
<s0>Oligodésoxyribonucléotide</s0>
</fC03>
<fC03 i1="18" i2="X" l="FRE">
<s0>Inhibition</s0>
</fC03>
<fC03 i1="19" i2="X" l="FRE">
<s0>Antiviral</s0>
</fC03>
<fC03 i1="21" i2="X" l="FRE">
<s0>Virus immunodéficience humaine</s0>
</fC03>
<fC03 i1="22" i2="X" l="FRE">
<s0>Phosphorothioate</s0>
<s4>INC</s4>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Analog</s0>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Oligonucleotide</s0>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Chemical synthesis</s0>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Synthetic product</s0>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Protection</s0>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Cytopathology</s0>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Viral disease</s0>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Dose activity relation</s0>
</fC03>
<fC03 i1="13" i2="X" l="ENG">
<s0>Cell culture</s0>
</fC03>
<fC03 i1="14" i2="X" l="ENG">
<s0>Infected cell</s0>
</fC03>
<fC03 i1="16" i2="X" l="ENG">
<s0>Oligodeoxyribonucleotide</s0>
</fC03>
<fC03 i1="18" i2="X" l="ENG">
<s0>Inhibition</s0>
</fC03>
<fC03 i1="19" i2="X" l="ENG">
<s0>Antiviral</s0>
</fC03>
<fC03 i1="21" i2="X" l="ENG">
<s0>Human immunodeficiency virus</s0>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Análogo</s0>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Oligonucleótido</s0>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Síntesis química</s0>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Producto sintético</s0>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Protección</s0>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Citopatología</s0>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Virosis</s0>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Relación dosis respuesta</s0>
</fC03>
<fC03 i1="13" i2="X" l="SPA">
<s0>Cultivo celular</s0>
</fC03>
<fC03 i1="14" i2="X" l="SPA">
<s0>Célula infectada</s0>
</fC03>
<fC03 i1="16" i2="X" l="SPA">
<s0>Oligodesoxirribonucleótido</s0>
</fC03>
<fC03 i1="18" i2="X" l="SPA">
<s0>Inhibición</s0>
</fC03>
<fC03 i1="19" i2="X" l="SPA">
<s0>Antiviral</s0>
</fC03>
<fC03 i1="21" i2="X" l="SPA">
<s0>Human immunodeficiency virus</s0>
</fC03>
<fC04 i1="01" i2="X">
<s0>PS21!04,26,19</s0>
</fC04>
<fC07 i1="01" i2="X" l="FRE">
<s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Retroviridae</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Virus</s0>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Infection</s0>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Retroviridae</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Virus</s0>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Infección</s0>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Retroviridae</s0>
</fC07>
<fC07 i1="09" i2="X" l="SPA">
<s0>Virus</s0>
</fC07>
<fN21>
<s1>005</s1>
</fN21>
</pA>
</standard>
<server>
<NO>PASCAL 90-0168889 INIST</NO>
<ET>Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of De Novo infection by HIV</ET>
<AU>STEIN (C. A.); MATSUKURA (M.); SUBASINGHE (C.); BRODER (S.); COHEN (J. S.)</AU>
<AF>National cancer inst./Bethesda MD 20892/Etats-Unis (A11011000)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>AIDS research and human retroviruses; ISSN 53157X; Coden ARHRE7; Etats-Unis; Da. 1989; Vol. 5; No. 6; Pp. 639-646; Bibl. 19 ref.</SO>
<LA>Anglais</LA>
<EA>We have now synthesized a series of phosphorothioate oligomers with mixed-based sequences and found that all of them have a dose-dependent cytoprotective effect that is maximal at an oligomer concentration of about 1-2 μM. The least effective sequences contain only A or T, and the most effective sequences have 40% GC content or greater. The results also confirm the length effect, namely that 21-mers are more cytoprotective than 14-mers</EA>
<CC>002A05C08</CC>
<FD>Analogue; Oligonucléotide; Synthèse chimique; Produit synthétique; Protection; Cytopathologie; Virose; Relation dose réponse; Culture cellulaire; Cellule infectée; Oligodésoxyribonucléotide; Inhibition; Antiviral; Virus immunodéficience humaine; Phosphorothioate</FD>
<FG>Infection; Retroviridae; Virus</FG>
<ED>Analog; Oligonucleotide; Chemical synthesis; Synthetic product; Protection; Cytopathology; Viral disease; Dose activity relation; Cell culture; Infected cell; Oligodeoxyribonucleotide; Inhibition; Antiviral; Human immunodeficiency virus</ED>
<EG>Infection; Retroviridae; Virus</EG>
<SD>Análogo; Oligonucleótido; Síntesis química; Producto sintético; Protección; Citopatología; Virosis; Relación dosis respuesta; Cultivo celular; Célula infectada; Oligodesoxirribonucleótido; Inhibición; Antiviral; Human immunodeficiency virus</SD>
<LO>CNRS-20934</LO>
<ID>90-0168889</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000118 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000118 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:90-0168889
   |texte=   Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of De Novo infection by HIV
}}
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021